BPC-157 vs TB-500: Differences, Evidence & 2026 Status

BPC-157 and TB-500 are both unapproved repair-oriented peptides, but they are different molecules with different origins. BPC-157 is a 15-amino-acid synthetic sequence derived from a protein found in human gastric juice; TB-500 is a synthetic product built around a short fragment of thymosin beta-4, a 43-amino-acid actin-binding protein. Almost all evidence for both is preclinical. In July 2026 an FDA advisory committee voted 8–6 (1 abstention) to recommend each for the 503A Bulks List, but neither is on that list until FDA completes rulemaking.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

BPC-157 vs TB-500 at a Glance

For a head-to-head between BPC-157 and the full-length thymosin beta-4 protein, see our thymosin beta-4 vs BPC-157 comparison. This article is about the TB-500 product specifically, which is not the same thing.

Where Each Peptide Comes From

BPC-157

BPC-157 is a pentadecapeptide — 15 amino acids — described as a partial sequence of a "body protection compound" isolated from human gastric juice [1]. It does not correspond to a known circulating hormone, and no country has approved a drug product containing it. Its research literature comes overwhelmingly from a small number of laboratories and from rodent models of gut injury and musculoskeletal damage.

TB-500

TB-500 is a commercial name rather than a pharmacological one. It is marketed as a synthetic version of the active region of thymosin beta-4 (Tβ4), a 43-amino-acid protein that binds actin and is found in almost all nucleated cells. When a Belgian anti-doping laboratory analyzed TB-500 material, it identified the N-terminal acetylated 17–23 fragment of Tβ4 (Ac-LKKTETQ) and developed tests to detect it in plasma and urine [2]. In other words, much of what is said about "TB-500" is borrowed from research on full-length Tβ4, a much larger molecule.

That distinction matters. Full-length Tβ4 has been studied in rat wound models [3] and progressed into human trials as an eye drop for dry eye and neurotrophic keratopathy [4]. Those data do not automatically apply to a seven-amino-acid fragment given by a different route. FDA's own Category 2 summary states that it has not identified any human exposure data for drug products containing the thymosin beta-4 fragment.

Mechanism: How They Are Thought to Work

The two peptides are usually described as complementary because their proposed mechanisms point at different parts of the repair process.

BPC-157. In cultured rat Achilles tendon explants, BPC-157 accelerated tendon fibroblast outgrowth, improved cell survival under oxidative stress, and increased fibroblast migration, without directly increasing proliferation [1]. Later work from the same group found that BPC-157 increased growth hormone receptor expression in rat tendon fibroblasts [9]. A 2025 systematic review summarized the preclinical literature as pointing to growth-factor signaling, angiogenesis pathways and reduced inflammatory cytokines [5].

TB-500 / thymosin beta-4. Tβ4's best-characterized function is sequestering G-actin, which influences cell shape and migration. In a rat full-thickness wound model, Tβ4 given topically or intraperitoneally increased re-epithelialization, wound contraction, collagen deposition and angiogenesis, and it stimulated keratinocyte migration in vitro [3]. A review of Tβ4's basic and clinical applications summarizes animal research in eye injuries, dermal wounds, cardiac repair after myocardial infarction and brain injury after stroke or trauma [6]. How much of this activity the short TB-500 fragment retains is not established in published human studies.

Evidence Level: What Has Actually Been Shown

BPC-157. A systematic review in HSS Journal screened 544 articles and included 36 studies — 35 preclinical and one clinical [5]. In animal models BPC-157 improved functional, structural and biomechanical outcomes after muscle, tendon, ligament and bone injury. The single clinical study was a retrospective chart review with a telephone follow-up survey of patients who had received intra-articular BPC-157, alone or with Tβ4, for knee pain at one clinic [7]. It had no control group and no validated outcome measures. A separate pilot reported tolerability of intravenous BPC-157 in two adults at a private clinic [8]. The review authors found no clinical safety data and reported a half-life for BPC-157 of under 30 minutes [5].

TB-500. There are no published randomized human trials of TB-500. The human data that exist are for full-length Tβ4, mainly ophthalmic formulations [4]. FDA's position is that it lacks human exposure data for the fragment.

Put plainly: for both peptides, the evidence base is animal and in-vitro work plus, for BPC-157, a handful of uncontrolled human reports. Neither has the dose-finding or efficacy trials that support an approved label.

Safety Considerations

Because neither peptide has gone through formal clinical development, the safety picture is mostly an absence of data rather than a documented profile.

• Limited human safety data. The BPC-157 systematic review found no clinical safety studies; preclinical toxicology showed no organ toxicity in animals [5]. FDA says it has identified "no, or only limited, safety-related information" for BPC-157's proposed routes, and no human exposure data for the TB-500 fragment (FDA's Category 2 safety-risk summary).

• Angiogenesis. Both are discussed for pro-angiogenic activity. In patients with active or recent malignancy this is a theoretical concern that has not been tested either way.
• Product identity. Much of the TB-500 and BPC-157 in circulation is sold as "research use only" material with no pharmaceutical quality controls. The anti-doping analysis of TB-500 illustrates that what is in a vial labeled TB-500 must be determined analytically [2].
• Immunogenicity and impurities. Peptide impurities from synthesis can be immunogenic — one reason FDA's compounding review weighs characterization and manufacturing data.

Dosing and route decisions belong to the prescriber, and we do not publish them. For BPC-157's adverse-event discussion in more depth, see BPC-157 side effects.

2026 Regulatory Status

Neither BPC-157 nor TB-500 is an FDA-approved drug. Both were previously in 503A Category 2 ("significant safety risks"); FDA's Category 2 safety-risk summary now lists both among substances whose nominations were withdrawn, and neither appears on FDA's Category 1 list (updated May 14, 2026).

At the July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting, the committee voted to recommend adding BPC-157 and TB-500 to the 503A Bulks List — each 8 yes, 6 no, 1 abstention — against FDA staff, whose briefing documents proposed listing neither. The votes are advisory. Neither substance is on the 503A Bulks List until FDA completes notice-and-comment rulemaking, which is expected to run into 2027. Track updates on the FDA Peptide Status Tracker, and see our deeper write-ups on BPC-157's 503A decision and TB-500's 503A decision.

Both are prohibited at all times for athletes under the WADA Prohibited List: BPC-157 under S0 (non-approved substances) and TB-500 under S2 (thymosin-β4 and its derivatives).

BPC-157 or TB-500: How the Choice Is Usually Framed

Clinicians who discuss these peptides tend to frame BPC-157 as the option with the larger musculoskeletal and gastrointestinal preclinical literature, and TB-500 as a systemic "migration and angiogenesis" option whose rationale comes largely from full-length Tβ4. Neither framing is supported by comparative human data — no study has compared them head to head.

Because the two are often discussed together, many readers are really asking about the combination; that is covered in the Wolverine Stack: BPC-157 and TB-500 together. For the broader category, our peptides for healing hub places both alongside repair peptides with a clearer regulatory position.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with licensed 503A partner pharmacies that together cover all 50 states and D.C.; prescribers can start at For Providers.

Frequently Asked Questions

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid peptide derived from a gastric protein, studied mainly for gut, tendon and ligament repair in animals. TB-500 is a synthetic product based on a short fragment of thymosin beta-4, an actin-binding protein. They have different origins, proposed mechanisms and research literatures.

Is BPC-157 or TB-500 better for tendon injuries?

No human study has compared them. BPC-157 has more tendon-specific preclinical work, including tendon fibroblast and rat Achilles models, while TB-500's rationale comes mostly from full-length thymosin beta-4 research. Neither has controlled human trial data for tendon healing.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-amino-acid protein; TB-500 is a synthetic product in which an anti-doping lab identified the acetylated 17–23 fragment of Tβ4. Research on the full-length protein does not automatically apply to TB-500.

Are BPC-157 and TB-500 FDA approved?

Neither is FDA approved. In July 2026 the PCAC voted 8–6 with one abstention to recommend each for the 503A Bulks List, but the vote is advisory and neither is on the list until FDA finishes rulemaking. Check the FDA Peptide Status Tracker for current status.

Are BPC-157 and TB-500 banned in sports?

Yes. WADA prohibits BPC-157 under S0 (non-approved substances) and TB-500 under S2 (thymosin-β4 and its derivatives), both at all times. Athletes subject to testing should treat both as prohibited.

What are the side effects of BPC-157 and TB-500?

Formal human safety data are essentially absent for both. FDA reports limited safety information for BPC-157 and no human exposure data for the TB-500 fragment. Theoretical concerns include angiogenesis in patients with cancer history, immunogenicity, and uncertain product identity in unregulated supply.

References

1. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. PubMed
2. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed
3. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PubMed
4. Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. 2018;18(sup1):99-104. PubMed
5. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PubMed
6. Goldstein AL, et al. Advances in the basic and clinical applications of thymosin β4. Expert Opin Biol Ther. 2015;15 Suppl 1:S139-45. PubMed
7. Lee E, et al. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PubMed
8. Lee E, et al. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PubMed
9. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-77. PubMed